KIF14在肝细胞癌SMCC-7721获得性耐药机制中的研究

doi:10.11904/j.issn.1002-3070.2022.01.003

Abstract

Abstract: Objective The objective of this study was to explore the relationship between inhibition of KIF14 and acquired resistance of hepatocellular carcinoma(HCC)SMCC-7721 cells to sorafenib.Methods The concentration gradient method was used to establish the HCC sorafenib-resistant SMCC-7721-SR cell line,and then the CCK-8 method and flow cytometry were used to verify resistant cell properties of the drug-resistant cell line.The qRT-PCR and Western blot assays were used to determine the expression of KIF14 in human normal liver LO2 cells,HCC SMCC-7721 cells and drug-resistant SMCC-7721-SR cells.Subsequently,KIF14-specific small interfering RNA(siKIF14)was used to knock down KIF14 and the KIF14 level was verified by Western blot;in order to explore the effect of knocking down KIF14 combined with sorafenib on HCC sorafenib-resistant cells,the CCK-8 method was used to detect cell viability,and flow cytometry was used to detect cell apoptosis.Results Compared with LO2 cells,the expression of KIF14 in SMCC-7721 cells was increased(P＜0.01),and the expression of KIF14 in SMCC-7721-SR cells was also increased when compared with SMCC-7721 cells(P＜0.01).Knocking down KIF14 expression could synergistically sorafenib inhibit the cell viability of SMCC-7721-SR cells and promote cell apoptosis(P＜0.01).Conclusion KIF14 is involved in the process of HCC and regulates the acquired sorafenib resistance of SMCC-7721 cells.Inhibiting the KIF14 expression could enhance the sensitivity of SMCC-7721-SR cells to sorafenib.

Key words: Hepatocellular carcinoma, KIF14, Sorafenib, Drug resistance

CLC Number:

R735.7

WANG Zongwen, LI Xiaodong, ZHU Qiankun, ZENG Shicong, ZHAI Bo. KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells[J]. Journal of Practical Oncology, 2022, 36(1): 14-19.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.01.003

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I1/14

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Feng RM,Zong YN,Cao SM,et al.Current cancer situation in China:good or bad news from the 2018 Global Cancer Statistics?[J].Cancer Commun(Lond),2019,39(1):22.
3 Zhai B,Sun XY.Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma[J].World J Hepatol,2013,5(7):345-352.
4 Llovet JM,Villanueva A,Lachenmayer A,et al.Advances in targeted therapies for hepatocellular carcinoma in the genomic era[J].Nat Rev Clin Oncol,2015,12(7):408-424.
5 Prieto-Dominguez N,Ordonez R,Fernandez A,et al.Modulation of autophagy by sorafenib:effects on treatment response[J].Front Pharmacol,2016,7:151.
6 Zhu Q,Ren H,Li X,et al.Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma[J].Aging(Albany NY),2020,12(22):22975-23003.
7 Hung PF,Hong TM,Hsu YC,et al.The motor protein KIF14 inhibits tumor growth and cancer metastasis in lung adenocarcinoma[J].PLoS One,2013,8(4):e61664.
8 Ahmed SM,Theriault BL,Uppalapati M,et al.KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression[J].J Cell Biol,2012,199(6):951-967.
9 Darwiche W,Gomila C,Ouled-Haddou H,et al.Ascorbic acid(vitamin C)synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia[J].J Exp Clin Cancer Res,2020,39(1):228.
10 Llovet JM,Villanueva A,Lachenmayer A,et al.Advances in targeted therapies for hepatocellular carcinoma in the genomic era[J].Nat Rev Clin Oncol,2015,12(7):408-424.
11 Feng J,Dai W,Mao Y,et al.Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis[J].J Exp Clin Cancer Res,2020,39(1):24.
12 Xia S,Pan Y,Liang Y,et al.The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma[J].EBio Medicine,2020,51:102610.
13 Chen KF,Chen HL,Tai WT,et al.Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells[J].J Pharmacol Exp Ther,2011,337(1):155-161.
14 Wang ZZ,Yang J,Jiang BH,et al.KIF14 promotes cell proliferation via activation of Akt and is directly targeted by miR-200c in colorectal cancer[J].Int J Oncol,2018,53(5):1939-1952.
15 Zhai B,Jiang X,He C,et al.Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation[J].Tumour Biol,2015,36(4):2323-2334.
16 Zhai B,Hu F,Yan H,et al.Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma:the role of endoplasmic reticulum stress[J].PLoS One,2015,10(9):e0138485.

[1]	LIU Fei, SUI Hong. Research progress in molecular classification of liver cancer based on tumor immunological microenvironment [J]. Journal of Practical Oncology, 2021, 35(6): 557-561.
[2]	JI Lei, JI Daolin, BAO Dongdong, TAN Gang. The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 562-567.
[3]	ZHAO Haoran, LI Man, ZHANG Yubao. Research progress of hepatocellular carcinoma-related RNA binding protein [J]. Journal of Practical Oncology, 2021, 35(6): 576-579.
[4]	HE Ling, YAO Kecheng. Glycosylphosphatidylinositol transamidase and hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 458-461.
[5]	LI Yuying, ZHANG Yue. Research progress of Sirtuins in breast cancer [J]. Journal of Practical Oncology, 2021, 35(3): 277-281.
[6]	GUO Piaoting, ZOU Yang. LncRNA SOX2OT sponge adsorbs miR-34a to promote SOX2 expression and enhance multidrug resistance in colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(5): 398-403.
[7]	ZHOU Jian,CHEN Xuejian,WANG Wei,LI Ning,SUN Zhenyu,XU Lishan. The effect of silencing PRMT5 gene in biological behavior of human hepatocellular carcinoma cells [J]. Journal of Practical Oncology, 2020, 34(3): 208-213.
[8]	ZHANG Congyi, CUI Yifeng, LI Baobao, LIU Lianxin. Expression of cell division cycle 7 protein in hepatocellular carcinoma tissues and its effect on proliferation and invasion of hepatocellular carcinoma cells [J]. Journal of Practical Oncology, 2020, 34(2): 150-155.
[9]	LIANG Yongqin, ZHAO Hongwei. Application progress of antiangiogenic drugs in platinum-resistant ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(1): 60-63.
[10]	CHEN Ziyin, BAI Yanchun, CAO Yangsen, LI Jian, XU Lili, ZHAO Qiushuang, WANG Yang. Dosimetry advantage of respiratory gating in the treatment of hepatocellular carcinoma with large segmentation [J]. Journal of Practical Oncology, 2019, 33(6): 536-539.
[11]	HUANG Xianbo, SHI Ting, YE Xiujin. Progress in the treatment of acute T lymphoblastic leukemia by targeting PI3K/AKT/mTOR pathway [J]. Journal of Practical Oncology, 2019, 33(5): 451-455.
[12]	QU Yanfei, LIU Chao, WANG Bojun, FANG Lin, ZHANG Yanqiao. Expression of CSN6 gene in hepatocellular carcinoma tissues and its clinical significance [J]. Journal of Practical Oncology, 2019, 33(4): 328-333.
[13]	HE Wei, MU Qiming, WANG Gang, WAN Bo, LIAO Bo, YANG Juan. Expression of TACC3 and p53 protein in primary liver cancer and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 420-425.
[14]	SHI Xiaokang, DING, Youming. Research progress on the relationship between helicobacter and primary hepatocellular carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 271-274.
[15]	WEN Juanjuan, QU Bing, LIU Chao. Clinical significance of antithrombin Ⅲ gene expression in hepatocellular carcinoma tissues [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 117-121.

KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments